MedTrace Logo

Comparing Salmeterol/Fluticasone Easyhaler and Seretide Diskus (SAIMI)

NCT03238482 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2018-04-06

No results posted yet for this study

Summary

The purpose of this study is to compare absorption of salmeterol and fluticasone from Salmeterol/fluticasone Easyhaler test products to the commercially available product Seretide Diskus

Conditions

Interventions

DRUG

salmeterol-fluticasone

Seretide Diskus 50/250 µg/dose

DRUG

salmeterol-fluticasone

Salmeterol/fluticasone Easyhaler 50/250 µg/dose, product E

DRUG

salmeterol-fluticasone

Salmeterol/fluticasone Easyhaler 50/250 µg/dose, product F

DRUG

salmeterol-fluticasone

Salmeterol/fluticasone Easyhaler 50/250 µg/dose, product G

Sponsors & Collaborators

  • Orion Corporation, Orion Pharma

    lead INDUSTRY

Principal Investigators

  • Ulla Sairanen · Orion Corporation, Orion Pharma

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-08-16
Primary Completion
2017-12-19
Completion
2017-12-19

Countries

  • Finland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03238482 on ClinicalTrials.gov